Please join us for a Reuters Newsmaker featuring Dr. Robert Califf, Commissioner of the U.S. Food and Drug Administration

Drug regulators around the world face a growing challenge to balance safety with innovation. As the arbiter of the gold standard in drug safety, the U.S. Food and Drug Administration finds itself in a post-pandemic world where trust in health officials is waning and medical misinformation is on the rise.

Rapidly evolving discoveries in fields such as obesity and Alzheimer’s treatments, along with an increasing number of gene therapies, show great promise but also pose new risks. Califf, an FDA veteran serving his second term as commissioner, discusses the agency’s response and priorities for the year ahead in a conversation with Reuters U.S. Healthcare and Pharma Editor Caroline Humer.